VarCov Co’s Haemonetics HAE Stock Holding History

VarCov Co’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,264	Closed	-$748K	–	446
2026 Q1	$748K	Buy	+13,264	New	+$864K	0.28%	134

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VarCov Co's HAE Position: Q2 2026 in Review

VarCov Co sold out of Haemonetics (HAE) in Q2 2026, closing a stake of 13,264 shares — an estimated $748K sold.

VarCov Co first reported a position in HAE in Q1 2026 and held it in 1 quarter. The position peaked at $748K in Q1 2026. 327 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

VarCov Co reported no remaining Haemonetics position as of Q2 2026 after selling out during the quarter.
VarCov Co sold 13,264 Haemonetics shares in Q2 2026, an estimated $748K.
VarCov Co first reported a position in Haemonetics in Q1 2026 and held it in 1 quarter.
VarCov Co's Haemonetics position peaked at $748K in Q1 2026.
327 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on VarCov Co's 13F filing for Q2 2026, filed 14 Aug 2026.